{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:45:07Z","timestamp":1760204707742},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40121-014-0035-9","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T11:39:04Z","timestamp":1409744344000},"page":"215-223","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study"],"prefix":"10.1007","volume":"3","author":[{"given":"Laurence","family":"Legout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piervito","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Sarraz-Bournet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Ettahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Haulon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Senneville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,4]]},"reference":[{"issue":"6","key":"35_CR1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/jac\/dki382","volume":"56","author":"SF FitzGerald","year":"2005","unstructured":"FitzGerald SF, Kelly C, Humphreys H. Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. J Antimicrob Chemother. 2005;56(6):996\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"35_CR2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0002-9610(85)90007-8","volume":"150","author":"RA Yeager","year":"1985","unstructured":"Yeager RA, McConnell DB, Sasaki TM, Vetto RM. Aortic and peripheral prosthetic graft infection: differential management and causes of mortality. Am J Surg. 1985;150(1):36\u201343.","journal-title":"Am J Surg"},{"issue":"4","key":"35_CR3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1469-0691.2011.03618.x","volume":"18","author":"L Legout","year":"2012","unstructured":"Legout L, Sarraz-Bournet B, D'Elia PV, et al. Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study. Clin Microbiol Infect. 2012;18(4):352\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"35_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jvs.2006.02.053","volume":"44","author":"S O'Connor","year":"2006","unstructured":"O'Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. J Vasc Surg. 2006;44(1):38\u201345.","journal-title":"J Vasc Surg"},{"issue":"4","key":"35_CR5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijantimicag.2008.08.029","volume":"33","author":"K Smith","year":"2009","unstructured":"Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents. 2009;33(4):374\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"35_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.amjsurg.2006.04.009","volume":"192","author":"CE Edmiston Jr","year":"2006","unstructured":"Edmiston CE Jr, Goheen MP, Seabrook GR, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg. 2006;192(3):344\u201354.","journal-title":"Am J Surg"},{"issue":"7","key":"35_CR7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med"},{"key":"35_CR8","doi-asserted-by":"crossref","unstructured":"New MRSA guidelines highlight a dearth of evidence. Lancet Infect Dis. 2011;11(3):153.","DOI":"10.1016\/S1473-3099(11)70040-8"},{"issue":"3","key":"35_CR9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1078155206069165","volume":"12","author":"MR Green","year":"2006","unstructured":"Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006;12(3):179\u201381.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"35_CR10","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/jac\/dkn105","volume":"61","author":"AI Hidron","year":"2008","unstructured":"Hidron AI, Schuetz AN, Nolte FS, Gould CV, Osborn MK. Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother. 2008;61(6):1394\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"35_CR11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","volume":"49","author":"JS Lewis 2nd","year":"2005","unstructured":"Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49(4):1664\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"35_CR12","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1128\/JCM.43.10.5285-5287.2005","volume":"43","author":"MK Hayden","year":"2005","unstructured":"Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43(10):5285\u20137.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"35_CR13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ejvs.2010.08.009","volume":"40","author":"O Cirioni","year":"2010","unstructured":"Cirioni O, Mocchegiani F, Ghiselli R, et al. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg. 2010;40(6):817\u201322.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9","key":"35_CR14","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1128\/AAC.00134-09","volume":"53","author":"KL LaPlante","year":"2009","unstructured":"LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother. 2009;53(9):3880\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"35_CR15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.01570-12","volume":"57","author":"C Garrigos","year":"2013","unstructured":"Garrigos C, Murillo O, Lora-Tamayo J, et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign body infection by methicillin resistant Staphylococcus aureus (MRSA). Antimicrob Agents Chemother. 2013;57(1):606\u201310.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"35_CR16","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/AAC.00047-09","volume":"53","author":"AK John","year":"2009","unstructured":"John AK, Baldoni D, Haschke M, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother. 2009;53(7):2719\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"35_CR17","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.00102-08","volume":"52","author":"WE Rose","year":"2008","unstructured":"Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2008;52(9):3061\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"35_CR18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","volume":"50","author":"L Cui","year":"2006","unstructured":"Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(3):1079\u201382.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"35_CR19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/cid\/cir805","volume":"54","author":"E Durante-Mangoni","year":"2012","unstructured":"Durante-Mangoni E, Casillo R, Bernardo M, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis. 2012;54(3):347\u201354.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"35_CR20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","volume":"31","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicentre, retrospective study. Pharmacotherapy. 2011;31(6):527\u201336.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"35_CR21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.eimc.2011.02.012","volume":"29","author":"J Parra-Ruiz","year":"2011","unstructured":"Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, Pomares-Mora J, Hernandez-Quero J. Efficacy and safety of high dose (\u22658\u00a0mg\/kg\/day) daptomycin. Enferm Infecc Microbiol Clin. 2011;29(6):425\u20137.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"2","key":"35_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","volume":"49","author":"DA Figueroa","year":"2009","unstructured":"Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177\u201380.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"35_CR23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0022-4804(77)90031-2","volume":"22","author":"AJ Roon","year":"1977","unstructured":"Roon AJ, Malone JM, Moore WS, Bean B, Campagna G. Bacteremic infectability: a function of vascular graft material and design. J Surg Res. 1977;22(5):489\u201398.","journal-title":"J Surg Res"},{"issue":"2","key":"35_CR24","first-page":"211","volume":"78","author":"JM Malone","year":"1975","unstructured":"Malone JM, Moore WS, Campagna G, Bean B. Bacteremic infectability of vascular grafts: the influence of pseudointimal integrity and duration of graft function. Surgery. 1975;78(2):211\u20136.","journal-title":"Surgery"},{"key":"35_CR25","unstructured":"Van Hal SJ, Paterson DL, Lodise TP. Vancomycin-induced nephrotoxicity in troughs of 15\u201320\u00a0mg\/L era: a systematic analysis review and meta-analysis. Antimicrob Agents Chemother. 2012 (Epub ahead of print)."},{"key":"35_CR26","unstructured":"Comit\u00e9 de l\u2019Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. http:\/\/www.sfm.asso.fr . Accessed August 2014."},{"key":"35_CR27","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1345\/aph.1R158","volume":"46","author":"A Horey","year":"2012","unstructured":"Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother. 2012;46:1477\u201383.","journal-title":"Ann Pharmacother"},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"35_CR29","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"B Dvorchik","year":"2003","unstructured":"Dvorchik B, Brazier D, De Bruin M, Arbeit R. Daptomycin phramacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"35_CR30","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/504379","volume":"42","author":"S Papadopoulos","year":"2006","unstructured":"Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006;42:e108\u201310.","journal-title":"Clin Infect Dis"},{"key":"35_CR31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jac\/dki476","volume":"57","author":"A Kazory","year":"2006","unstructured":"Kazory A, Dibadj K, Weiner D. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother. 2006;57:578\u20139.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-014-0035-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T19:48:58Z","timestamp":1498160938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-014-0035-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s40121-014-0035-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,4]]}}}